LHRH agonists in prostate cancer: Frequency of treatment, serum testosterone measurement and castrate level: Consensus opinion from a roundtable discussion

Current Medical Research and Opinion

Volumn 23, Issue 5, 2007, Pages 1077-1080

  De Jong, Igle Jan ^a   Eaton, Alan ^b   Bladou, Franck ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

LHRH agonists; Prostate neoplasms; Testosterone

Indexed keywords

BICALUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

CASTRATION; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; ORCHIECTOMY; OUTCOME ASSESSMENT; PATIENT MONITORING; PROGNOSIS; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CONSENSUS; DRUG ADMINISTRATION SCHEDULE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 34249006896     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X187973     Document Type: Conference Paper

References (17)

1. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients' choice of treatment in stage D prostate cancer. Urology 1989;33(5 Suppl):57-62
2. Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989;33(5 Suppl):45-52
3. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-8
4. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 1995;46:220-6
5. Marks LS. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Urology 2003;62(6 Suppl 1):36-42
6. Abrahamsson PA, Anderson J, Boccon-Gibod L, et al. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer. Eur Urol 2005;48:900-5
7. Heidenreich A, Aus G, Abbou CC, et al. EAU guidelines on prostate cancer. 2007. Available at http://www.uroweb.org/flleadmin/user_upload/Guidelines/ 07_Prostate_Cancer_2007.pdf [Last accessed 1 April 2007]
8. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51
9. Kaisary AV, Tyrrell CJ, Beacock C, et al. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Eur Urol 1995;28:215-22
10. Iversen PC, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared witJi castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51:389-96
11. Zlotta AR, Abrahamsson PA, Tombal P, et al. Hormone therapy: improving therapy decisions and monitoring. Eur Urol Suppl 2006;5:369-76
12. Maatman TJ, Gupta MJ, Montie JE. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol 1985;133:620-1
13. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004;92:287-95
14. Rohl HF, Beuke HP. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992;26:11-14
15. Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021-4
16. Seidenfeld J, Samson DV, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566-77
17. Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology 1999;54:694-9